TOAD Oncology

TOAD Oncology is a biotechnology company and University of Oxford spin-out dedicated to overcoming tumor hypoxia, a significant barrier to effective cancer treatment. The company's core technology, the Tumor-Oxygenating Aerobic Device (TOAD), utilizes oxygen-loaded nanobubbles to deliver oxygen directly into the core of hypoxic solid tumors. By re-oxygenating the tumor microenvironment, the platform aims to sensitize tumors to conventional therapies such as radiotherapy and chemotherapy, which are often less effective in low-oxygen conditions. Currently in the pre-clinical phase, TOAD Oncology is focusing its efforts on challenging indications, including pancreatic cancer, where hypoxia is a dominant feature of the disease. The company's innovative approach represents a potential shift in how treatment-resistant solid tumors are managed in clinical oncology.